Table 1 Demographic and clinical characteristics at initial visit of 302 patients with MF who received upfront JAKi or HCT.

From: Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study

Characteristic

Upfront JAKia n = 213

Upfront HCT n = 89

P value

Age

    - Median (range)

61 (16–70)

57 (28–69)

<0.01

Diagnosis, n (%)

    - PMF

117 (55)

54 (61)

0.14

    - Post-ET MF

46 (22)

23 (26)

 

    - Post-PV MF

50 (23)

12 (13)

 

Gender, n (%)

    - Female

79 (37)

33 (37)

1.00

    - Male

134 (63)

56 (63)

 

DIPSS, n (%)b

    - Intermediate-1

98 (46)

28 (31)

0.01

    - Intermediate-2

94 (44)

56 (63)

 

    - High

21 (10)

5 (6)

 

Transfusion-requiring anemia, n (%)

    - Yes

172 (81)

61 (69)

0.03

    - No

41 (19)

28 (31)

 

Thrombocytopenia, platelet count <100 × 109/L

    - Yes

171 (80)

71 (80)

1.00

    - No

42 (20)

18 (20)

 

Driver mutation, n (%)

    - JAK2

147 (69)

53 (60)

0.42

    - CALR

20 (9)

7 (8)

 

    - MPL

7 (3)

3 (3)

 

    - Triple negative

6 (3)

5 (6)

 

    - Two driver mutations

3 (1)

1 (1)

 

    - Unknown

30 (14)

20 (22)

 

High molecular risk, n (%)c

    - Yes

40 (19)

21 (24)

0.61

    - No

36 (17)

13 (15)

 

    - Unavailable

137 (64)

55 (62)

 

Cytogenetics, n (%)

    - Normal

78 (37)

35 (39)

0.22

    - Unfavorabled

22 (10)

16 (18)

 

    - Other abnormal

37 (17)

12 (13)

 

    - Unavailable

76 (36)

26 (29)

 
  1. JAKi JAK inhibitor therapy, HCT allogeneic hematopoietic cell transplantation, MF myelofibrosis, PMF primary myelofibrosis, ET essential thrombocythemia, PV polycythemia vera, DIPSS dynamic international prognostic scoring system.
  2. aIn the upfront JAKi group 50 patients underwent subsequent HCT for JAKi failure.
  3. bAt the time of initiation of JAKi or HCT.
  4. cPathogenic mutation in at least one of the following genes: ASXL1, IDH1/2, SRSF2, EZH2, U2AF1 Q157.
  5. d+8, −7/7q-, i(17q), inv(3), −5/5q, 12p-, or 11q23 rearrangements.
Back to article page